Search results for " END"

showing 10 items of 4885 documents

Occurrence and timing of complications following traumatic dental injuries: A retrospective study in a dental trauma department

2016

Background This study explores the pattern of complications occurrence resulting from traumatic dental injuries, the relation of this pattern to the number of years from the time of the injury to its first diagnosis, and other contributing characteristics such as root development and trauma characteristic. Material and Methods Patients’ data treated following dental trauma from 2002 to 2014 were classified and grouped according to age, gender, tooth type, injury type, diagnosis and the time that elapsed between the traumatic event and the diagnosis of complications (TIC). The distribution function of the quantitative parameters was determined with the Kolmogorov-Smirnov test. Fisher exact t…

medicine.medical_specialtyDentistryOdontologíaOperative Dentistry and EndodonticsAvulsion030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicinestomatognathic systemmedicineMaxillary central incisorGeneral DentistryFisher's exact testPulp necrosisDental traumabusiness.industryResearchRetrospective cohort study030206 dentistrymedicine.diseaseCiencias de la saludSurgerystomatognathic diseasesTraumatic injurysymbolsUNESCO::CIENCIAS MÃ DICAS:CIENCIAS MÃ DICAS [UNESCO]businessComplicationJournal of Clinical and Experimental Dentistry
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Comparative characteristics of older people with type 1 diabetes treated with continuous subcutaneous insulin infusion or insulin injection therapy :…

2019

Aim To compare clinical characteristics and outcomes in adults with type 1 diabetes aged ≥ 60 years using continuous subcutaneous insulin infusion (CSII) vs. insulin injection therapy. Further, to determine the percentage of older adults with type 1 diabetes using CSII. Research design and methods Retrospective study using data of the Diabetes Prospective Follow-up Registry (DPV). Including percentage CSII use from 2008 to 2018, and the characteristics of 9547 individuals extracted from the DPV in March 2019 (N = 1404 CSII; N = 8143 insulin injection therapy). Wilcoxon rank sum tests were used for continuous variables and chi-square tests for categorical variables to compare clinical charac…

medicine.medical_specialtyDiabetic ketoacidosisEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicineDiabetes mellitus Type 1Internal MedicineMedicine030212 general & internal medicineddc:610ContraindicationDepression (differential diagnoses)AgedType 1 diabetesbusiness.industryInsulinCSIIDiabetes mellitus; TherapyDiabetes mellitus Typ 1Retrospective cohort studymedicine.diseaseInsulin infusion systems3. Good healthMicroalbuminuriaOlder peopleInsulinpumpebusinessAlter <60-90 Jahre>
researchProduct

Effects of nicotine receptor agonists on acetylcholine release from the isolated motor nerve, small intestine and trachea of rats and guinea-pigs

1992

The effects of nicotine receptor agonists on the release of [3H]acetylcholine from the phrenic nerve, the small intestine and the trachea were investigated to characterize neuronal nicotine receptors within the peripheral nervous system. Contraction of the indirectly-stimulated hemidiaphragm was recorded to investigate desensitization of the postsynaptic muscular nicotine receptors. Nicotine, cytisine, 1,1-dimethyl-4-phenylpiperazinium and 2-(4-aminophenyl)-ethyl-trimethyl-ammoniumiodide caused a concentration-dependent (0.1-30 microM) increase in evoked [3H]acetylcholine release from the phrenic nerve, whereby bell-shaped concentration-response curves were obtained. The rank order of decre…

medicine.medical_specialtyDiaphragmGuinea PigsMyenteric PlexusMotor nerveReceptors NicotinicMotor EndplateNicotineCytisinechemistry.chemical_compoundPostsynaptic potentialInternal medicineIntestine SmallDrug DiscoverymedicineAnimalsGenetics (clinical)Phrenic nerveDose-Response Relationship DrugMuscle SmoothGeneral MedicineAcetylcholineStimulation ChemicalRatsPhrenic NerveTracheaEndocrinologymedicine.anatomical_structureParasympathomimeticschemistryPeripheral nervous systemMolecular Medicinemedicine.symptomSecretory RateAcetylcholineMuscle Contractionmedicine.drugMuscle contractionThe Clinical Investigator
researchProduct

Dietary therapy and non-surgical periodontal treatment in obese patients with chronic periodontitis.

2018

Aim The effect of dietary weight loss intervention on periodontal therapy is unknown. Therefore, we aimed to evaluate whether weight loss improves the response of obese subjects to non-surgical periodontal treatment. Materials and methods This interventional study in obese patients was conducted at the University Hospital Dr. Peset (Valencia, Spain). Patients were divided into two groups with and without dietary therapy. All participants received non-surgical periodontal treatment. Periodontal, anthropometric and biochemical parameters were assessed at baseline and 12 weeks. Results A total of 78 patients were re-evaluated after intervention. All periodontal parameters improved in both grou…

medicine.medical_specialtyDiet therapy030209 endocrinology & metabolismSystemic inflammationGastroenterology03 medical and health sciences0302 clinical medicineWeight lossInternal medicinePeriodontal Attachment LossWeight LossMedicineHumansObesityPeriodontitisComplement component 3business.industry030206 dentistryAnthropometrymedicine.diseaseChronic periodontitisObesitySpainChronic PeriodontitisPeriodonticsmedicine.symptomPeriodontal IndexbusinessJournal of clinical periodontology
researchProduct

Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in Fran…

2018

Background One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis associated with amoxicillin for IE AP. Material and Methods The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostrid…

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsMedDRA03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilanceHumansMedicineEndocarditisAntibiotic prophylaxisGeneral DentistryOral Medicine and PathologyEndocarditisbusiness.industryResearchClindamycinEndocarditis Bacterial030206 dentistryAntibiotic ProphylaxisAmoxicillinClostridium difficilemedicine.disease:CIENCIAS MÉDICAS [UNESCO]3. Good healthOtorhinolaryngologyInfective endocarditisUNESCO::CIENCIAS MÉDICASSurgeryFrancebusinessmedicine.drug
researchProduct

Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction

2021

Abstract Introduction and objectives Angiogenesis helps to reestablish microcirculation after myocardial infarction (MI). In this study, we aimed to further understand the role of the antiangiogenic isoform vascular endothelial growth factor (VEGF)-A165b after MI and to explore its potential as a coadjuvant therapy to coronary reperfusion. Methods Two mice MI models were formed: a) permanent coronary ligation (nonreperfused MI); b) transient 45-minute coronary occlusion followed by reperfusion (reperfused MI); in both models, animals underwent echocardiography before euthanasia at day 21 after MI induction. We determined serum and myocardial VEGF-A165b levels. In both experimental MI models…

medicine.medical_specialtyEjection fractionbusiness.industryAngiogenesisGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseMicrocirculationBlockadeVascular endothelial growth factor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryCoronary occlusionHeart failureInternal medicinemedicineCardiologyMyocardial infarctionbusinessRevista Española de Cardiología (English Edition)
researchProduct

Infective endocarditis triangle.. Is it the time to revisit infective endocarditis susceptibility and indications for its antibiotic prophylaxis?

2019

medicine.medical_specialtyEndocarditisEpidemiologybusiness.industryMEDLINEAntibiotic ProphylaxisGlobal HealthPrognosismedicine.diseaseAnti-Bacterial AgentsSurvival RateBacterial endocarditisInfective endocarditismedicineHumansAntibiotic prophylaxisCardiology and Cardiovascular MedicinebusinessIntensive care medicineEuropean Journal of Preventive Cardiology
researchProduct

Diabetes mellitus secondary to Cushing's disease

2018

Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortis…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyCarbohydrate metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceCortisol-lowering medication; Cushing's disease; Diabetes; Glucocorticoids; Insulin resistance; Endocrinology Diabetes and MetabolismEndocrinologyInternal medicineDiabetes mellitusmedicineGlucocorticoidslcsh:RC648-665business.industryDiabetesInsulin resistanceCushing's diseaseCushing’s diseasemedicine.diseaseDiabetes and MetabolismEndocrinologyPostprandialCortisol-lowering medicationCushing's diseasePituitary surgerybusinessGlucocorticoidmedicine.drug
researchProduct